Keytruda, the world's top selling drug in 2024, has been Merck's key revenue driver over the past few years and is expected to top $30 billion
As for top drugs, Merck's cancer superstar Keytruda is projected to be the world s top-selling drug by a huge margin in 2024, according to the report.
Merck is a global health care company based in Kenilworth, New Jersey. The Merck's top-selling drug in FY 2024 was Keytruda, which is used to treat
Merck's cancer drug Keytruda is expected to be the top-selling drug globally in 2024, according to data published by Statista.
In head-to-head clinical trial, Chinese firm Akeso's ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck.
Merck Co.'s top-selling drugs 2024; The most important statistics. Top pharmaceutical products by sales worldwide 2024; Revenue of AbbVie's Humira ; Merck Co.'s Keytruda revenue 2024
Merck's PD-L1 inhibitor Keytruda was the best-selling cancer product in 2024 and is forecasted to be the top-selling pharmaceutical in 2024. Also read: NSCLC Drug Development Updates Keytruda (pembrolizumab) was approved for more than thirteen indications and is the best-selling product of Merck.
200 countries and territories Merck Co.'s top-selling drugs 2024; Merck Co.'s Keytruda revenue ; Sales forecast of top selling drugs worldwide 2024; The most important statistics.
Merck's top-selling multiple sclerosis drug Rebif, or a setback for the group's third bestselling drug, Erbitux, causing erosion in
Comments